- Home
- SLND vs MCRB Comparison
SLND vs MCRB Comparison
Compare SLND & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLND
- MCRB
- Stock Information
- Founded
- SLND 1900
- MCRB 2010
- Country
- SLND United States
- MCRB United States
- Employees
- SLND N/A
- MCRB N/A
- Industry
- SLND Military/Government/Technical
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- SLND Industrials
- MCRB Health Care
- Exchange
- SLND Nasdaq
- MCRB Nasdaq
- Market Cap
- SLND 175.8M
- MCRB 141.9M
- IPO Year
- SLND N/A
- MCRB 2015
- Fundamental
- Price
- SLND $2.98
- MCRB $0.68
- Analyst Decision
- SLND Strong Buy
- MCRB Hold
- Analyst Count
- SLND 1
- MCRB 5
- Target Price
- SLND $5.00
- MCRB $4.00
- AVG Volume (30 Days)
- SLND 58.7K
- MCRB 787.5K
- Earning Date
- SLND 03-04-2025
- MCRB 03-13-2025
- Dividend Yield
- SLND N/A
- MCRB N/A
- EPS Growth
- SLND N/A
- MCRB N/A
- EPS
- SLND N/A
- MCRB 0.00
- Revenue
- SLND $980,179,000.00
- MCRB N/A
- Revenue This Year
- SLND $4.06
- MCRB N/A
- Revenue Next Year
- SLND $7.16
- MCRB N/A
- P/E Ratio
- SLND N/A
- MCRB $772.80
- Revenue Growth
- SLND N/A
- MCRB N/A
- 52 Week Low
- SLND $1.85
- MCRB $0.54
- 52 Week High
- SLND $5.98
- MCRB $1.53
- Technical
- Relative Strength Index (RSI)
- SLND 38.56
- MCRB 41.45
- Support Level
- SLND $3.15
- MCRB $0.69
- Resistance Level
- SLND $3.23
- MCRB $0.76
- Average True Range (ATR)
- SLND 0.12
- MCRB 0.05
- MACD
- SLND -0.04
- MCRB -0.00
- Stochastic Oscillator
- SLND 2.00
- MCRB 29.07
About SLND Southland Holdings Inc.
Southland Holdings Inc is an infrastructure construction company in North America. The company's infrastructure projects range from water conveyance systems and tunnels to long-span bridges and vertical structures.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.